Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer.

导出 OA

翻译打印收藏纠错

第一作者： Samantha B,Kemp

第一单位： Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.;Abramson Cancer Center and Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

作者： Samantha B,Kemp ^[1] ; Noah,Cheng ^[1] ; Nune,Markosyan ^[1] ; Rina,Sor ^[1] ; Il-Kyu,Kim ^[1] ; Jill,Hallin ^[2] ; Jason,Shoush ^[1] ; Liz,Quinones ^[1] ; Natalie V,Brown ^[1] ; Jared B,Bassett ^[1] ; Nikhil,Joshi ^[1] ; Salina,Yuan ^[1] ; Molly,Smith ^[1] ; William P,Vostrejs ^[1] ; Kia Z,Perez-Vale ^[1] ; Benjamin,Kahn ^[1] ; Feiyan,Mo ^[1] ; Timothy R,Donahue ^[3] ; Caius G,Radu ^[3] ; Cynthia,Clendenin ^[1] ; James G,Christensen ^[2] ; Robert H,Vonderheide ^[4] ; Ben Z,Stanger ^[1]

作者单位： Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.;Abramson Cancer Center and Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. ^[1] Mirati Therapeutics, Inc., San Diego, California. ^[2] Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, California. ^[3] Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.;Abramson Cancer Center and Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.;Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, Pennsylvania. ^[4]